Navigation Links
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
Date:10/7/2008

company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about a Letter of Intent to negotiate terms and conditions potentially leading to a license agreement with AnGes for development and marketing of pandemic influenza DNA vaccines in Japan, as well as Vical's focus, collaborative partners, and product candidates. Risks and uncertainties include whether we will be able to complete a mutually satisfactory definitive agreement with AnGes; whether preliminary H5N1 DNA vaccine Phase 1 clinical trial results will be confirmed upon further analysis or in larger studies; whether any product candidates under development by Vical or its collaborative partners will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vical to Present at UBS Global Life Sciences Conference
2. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
3. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
4. Vical to Present at Upcoming Investor Conferences
5. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
6. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
7. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
8. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
9. Vical to Present at Cowen and Company Health Care Conference
10. Vical to Present at BIO and BVGH Global Health Partnering Event
11. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... will be Centerpiece to Expansion of ... Radiation Oncology Facility, ... ), a global leader in the field of radiosurgery,today announced ... Robotic Radiosurgery System to further expand treatment,offerings for its nationally ...
... 24 United,Therapeutics Corporation (Nasdaq: UTHR ) ... quarter financial results before the open of market,on ... host a half-hour teleconference on Thursday,July 31, 2008, ... accessible,by dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A ...
... VEDBAEK, Denmark, July 24 Frost & Sullivan,has announced ... 2008 Growth,Strategy Leadership Award in the molecular diagnostic market. ... the molecular diagnostic,market., Exiqon was selected for this ... leader in the field of in vitro therapy selection,testing ...
Cached Biology Technology:St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 2St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 3St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 4Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 2Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 3
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... A variety of end products including jet fuel, gasoline, ... existing refineries and combinations of coal and refinery by-products, ... idea is based on the coal-to-jet fuel work that ... Caroline E. Burgess Clifford, research associate at Penn State,s ...
... tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based ... transfer radical polymerization (ATRP), which will ultimately enable ... the target and to dispense the drug in ... 200 nanometers in diameter possess many unique ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
Cached Biology News:Coal-based fuels and products hit the refinery 2Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs 2Truly sick or simply scared? 2
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: